NASDAQ:PTCT PTC Therapeutics - PTCT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $48.44 -0.42 (-0.86%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$48.30▼$50.2050-Day Range$42.19▼$48.8652-Week Range$25.01▼$55.58Volume785,691 shsAverage Volume817,876 shsMarket Capitalization$3.58 billionP/E RatioN/ADividend YieldN/APrice Target$52.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability PTC Therapeutics MarketRank™ ForecastAnalyst RatingHold2.36 Rating ScoreUpside/Downside7.3% Upside$52.00 Price TargetShort InterestBearish7.38% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.07Based on 15 Articles This WeekInsider TradingSelling Shares$2.91 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.78) to ($3.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 starsMedical Sector861st out of 996 stocksPharmaceutical Preparations Industry418th out of 484 stocks 2.2 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.00, PTC Therapeutics has a forecasted upside of 7.3% from its current price of $48.44.Amount of Analyst CoveragePTC Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.38% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 9.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.Environmental SustainabilityThe Environmental Impact score for PTC Therapeutics is -1.38. Previous Next 2.3 News and Social Media Coverage News SentimentPTC Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for PTC Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for PTCT on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,909,307.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of PTC Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($4.78) to ($3.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About PTC Therapeutics (NASDAQ:PTCT) StockPTC Therapeutics, Inc. is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.Read More Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Stock News HeadlinesApril 1, 2023 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Sells $1,202,009.22 in StockMarch 31, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Stock Price Up 5.6%April 1, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 30, 2023 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Sells $331,335.00 in StockMarch 30, 2023 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells $451,000.00 in StockMarch 29, 2023 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) to Post Q1 2023 Earnings of ($0.87) Per Share, William Blair ForecastsMarch 28, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Hold Rating on PTC Therapeutics (PTCT)March 24, 2023 | markets.businessinsider.comPTC Therapeutics CEO Stuart Peltz To Retire; Names Matthew Klein CEOApril 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 23, 2023 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $52.00 Average Price Target from BrokeragesMarch 22, 2023 | finance.yahoo.comPTC Therapeutics, Inc. (PTCT)March 22, 2023 | nasdaq.comSVB Leerink Initiates Coverage of PTC Therapeutics (PTCT) with Market Perform RecommendationMarch 21, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Receives New Coverage from Analysts at SVB SecuritiesMarch 21, 2023 | americanbankingnews.comSVB Leerink Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT)March 19, 2023 | benzinga.comPTC Therapeutics Stock (NASDAQ:PTCT), Short Interest ReportMarch 17, 2023 | markets.businessinsider.comWhere PTC Therapeutics Stands With AnalystsFebruary 23, 2023 | finance.yahoo.comWhen Can We Expect A Profit From PTC Therapeutics, Inc. (NASDAQ:PTCT)?February 22, 2023 | benzinga.comLooking Into PTC Therapeutics's Return On Capital EmployedFebruary 22, 2023 | finanznachrichten.dePTC Therapeutics, Inc.: PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 22, 2023 | seekingalpha.comPTC Therapeutics GAAP EPS of -$2.35 misses by $0.78, revenue of $167.41M misses by $15.66MFebruary 21, 2023 | finance.yahoo.comPTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 21, 2023 | finance.yahoo.comPTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue EstimatesFebruary 13, 2023 | thestreet.comDeutsche Compares PTC Therapeutics To Vertex, Boosts Target By $40February 7, 2023 | finance.yahoo.comPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial ResultsFebruary 3, 2023 | finance.yahoo.comPTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for InnovationFebruary 2, 2023 | finance.yahoo.comPTC Therapeutics to Participate at Upcoming Investor ConferenceJanuary 27, 2023 | reuters.comPTCT.P - | Stock Price & Latest News | ReutersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Company Calendar Last Earnings2/21/2023Today4/01/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.00 High Stock Price Forecast$70.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+7.3%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($7.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-559,020,000.00 Net Margins-80.00% Pretax Margin-84.07% Return on EquityN/A Return on Assets-32.47% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.65 Sales & Book Value Annual Sales$698.80 million Price / Sales5.12 Cash FlowN/A Price / Cash FlowN/A Book Value($4.76) per share Price / Book-10.18Miscellaneous Outstanding Shares73,820,000Free Float69,386,000Market Cap$3.58 billion OptionableOptionable Beta0.40 Key ExecutivesStuart Walter PeltzChief Executive Officer & DirectorMatthew B. KleinChief Operating OfficerEmily HillChief Financial OfficerNeil Gregory AlmsteadChief Technical Operations OfficerEllen WelchChief Scientific OfficerKey CompetitorsMaravai LifeSciencesNASDAQ:MRVIZai LabNASDAQ:ZLABIVERIC bioNASDAQ:ISEECytokineticsNASDAQ:CYTKReata PharmaceuticalsNASDAQ:RETAView All CompetitorsInsiders & InstitutionsChristine Marie UtterSold 4,688 sharesTotal: $224,039.52 ($47.79/share)Emily Luisa HillSold 7,363 sharesTotal: $331,335.00 ($45.00/share)Christine Marie UtterSold 26,658 sharesTotal: $1.20 M ($45.09/share)David P SouthwellSold 10,000 sharesTotal: $451,000.00 ($45.10/share)Neo Ivy Capital ManagementBought 6,132 shares on 3/27/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions PTCT Stock - Frequently Asked Questions Should I buy or sell PTC Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares. View PTCT analyst ratings or view top-rated stocks. What is PTC Therapeutics' stock price forecast for 2023? 11 brokerages have issued 1-year target prices for PTC Therapeutics' stock. Their PTCT share price forecasts range from $35.00 to $70.00. On average, they expect the company's stock price to reach $52.00 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price. View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts. How have PTCT shares performed in 2023? PTC Therapeutics' stock was trading at $38.17 at the start of the year. Since then, PTCT stock has increased by 26.9% and is now trading at $48.44. View the best growth stocks for 2023 here. When is PTC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our PTCT earnings forecast. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its quarterly earnings results on Tuesday, February, 21st. The biopharmaceutical company reported ($2.35) EPS for the quarter, missing analysts' consensus estimates of ($1.96) by $0.39. The biopharmaceutical company earned $167.41 million during the quarter, compared to the consensus estimate of $183.07 million. The firm's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter last year, the business posted ($2.03) earnings per share. What ETFs hold PTC Therapeutics' stock? ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Direxion mRNA ETF (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Psyk Etf (PSYK), Invesco Dynamic Biotechnology & Genome ETF (PBE), Motley Fool Small-Cap Growth ETF (TMFS), MFAM Small-Cap Growth ETF (MFMS), Virtus LifeSci Biotech Products ETF (BBP) and Franklin Genomic Advancements ETF (HELX). What guidance has PTC Therapeutics issued on next quarter's earnings? PTC Therapeutics updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $940.00M-$1.00 billion, compared to the consensus revenue estimate of $898.56 million. What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO? 24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD). What is PTC Therapeutics' stock symbol? PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT." How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PTC Therapeutics' stock price today? One share of PTCT stock can currently be purchased for approximately $48.44. How much money does PTC Therapeutics make? PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.58 billion and generates $698.80 million in revenue each year. The biopharmaceutical company earns $-559,020,000.00 in net income (profit) each year or ($7.79) on an earnings per share basis. How many employees does PTC Therapeutics have? The company employs 1,410 workers across the globe. How can I contact PTC Therapeutics? PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231. This page (NASDAQ:PTCT) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.